ArticleFrontiers in neurology
Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Efgartigimod, an FcRn antagonist that reduces circulating immunoglobulin G (IgG), is approved for the treatment of acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). While its efficacy has been demonstrated in randomized clinical trials, real-world data describing longitudinal use and management of efgartigimod in routine clinical practice are still emerging. Methods: We conducted a retrospective observational study across two neuromuscular referral centers, including adults with AChR antibody-positive gMG treated with intravenous efgartigimod between April 2023 and August 2025. Treatment was initiated across a range of real-world clinical scenarios, including refractory disease, non-crisis symptom relapse, corticosteroid tapering, maintenance of minimal-symptom expression, and bridging before thymectomy or initiation of conventional immunosuppression. Retreatment intervals were individualized based on clinical course. Clinical outcomes, corticosteroid use, serological markers, adjunctive therapies, and safety events were analyzed descriptively. Results: Thirteen patients received a total of 52 efgartigimod treatment cycles. Most patients experienced repeated improvement in MG-Activities of Daily Living (MG-ADL) during treatment cycles, although clinical status varied over time. Corticosteroid doses were reduced in the majority of patients during follow-up. Episodes of clinically significant worsening occurred outside the setting of myasthenic crisis and were managed with established rescue therapies, after which efgartigimod could often be resumed. Treatment was generally well tolerated. Conclusion: This study describes how efgartigimod is integrated into routine clinical practice as part of longitudinal disease management for AChR antibody-positive gMG. Real-world use encompassed diverse clinical scenarios and required individualized retreatment decisions and ongoing reassessment. These findings highlight the role of FcRn blockade as a flexible therapeutic option that complements established therapy in everyday care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.